Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF3GM2)

• Drug Name: Somatropin recombinant Drug Info
• Synonyms: Genotropin (TN); Humatrope (TN); Norditropin (TN); Nutropin (TN); Saizen (TN)

Indication

Disease Entry	ICD 11	Status	REF
Fetal growth restriction	KA20.1Z	Approved	[1]
Growth hormone deficiency	5A61.3	Approved	[2]
Pituitary dwarfism		Approved	[3]
Turner syndrome		Approved	[4]

• Therapeutic Class: Hormone Replacement Agents
• Cross-matching ID:
  PubChem CID: 16132356
  TTD Drug ID: DMF3GM2

Molecule-Related Drug Atlas

Drug(s) Targeting Growth hormone receptor (GHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegvisomant	DMDEZI3	Acromegaly	5A60.0	Approved	[6]
SKF-110679	DMNRHMX	Growth hormone deficiency	5A61.3	Phase 2	[7]
PH-794428	DM71HVW	Growth hormone deficiency	5A61.3	Phase 2	[8]
IONIS-GHR-LRx	DMQ9711	Acromegaly	5A60.0	Phase 2	[9]
Syntropin	DMH76KD	Dwarfism	5B11	Phase 1	[10]
EP-51389	DMW739O	Eating disorder	6B82	Phase 1	[11]
EP-51216	DM49RI7	Eating disorder	6B82	Phase 1	[11]
AOD-9604	DMGDPSI	Obesity	5B81	Discontinued in Phase 2	[12]
BVT-A	DMDSX58	Acromegaly	5A60.0	Preclinical	[13]
NNC-26-0194	DMDCPFJ	Discovery agent	N.A.	Investigative	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth hormone receptor (GHR)	TTKMAZ6	GHR_HUMAN	Binder	[5]

References

• [1] Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Nat Rev Endocrinol. 2017 Feb;13(2):105-124.
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2717-e2728.
• [4] The use of somatropin (recombinant growth hormone) in children of short stature. Paediatr Drugs. 2002;4(1):37-47.
• [5] Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7.
• [6] Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093).
• [8] PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51.
• [9] ClinicalTrials.gov (NCT04522180) An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly. U.S.National Institutes of Health.
• [10] Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Psychoneuroendocrinology. 1998 May;23(4):371-83.
• [11] Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
• [12] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [13] Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93.
• [14] Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998 Nov;28(11):1083-92.